NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs021240026

Registered date:25/09/2024

The effictiveness of QLBi as postoperative analgesia after lumbar operation.

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedPatients undergoing lumbar fusion surgery
Date of first enrollment25/09/2024
Target sample size60
Countries of recruitment
Study typeInterventional
Intervention(s)In the QLBi group, QLBi will be performed bilaterally under ultrasound guidance. The medication used will be 0.25% ropivacaine 0.4 mL/kg per side (0.8 mL/kg per side, maximum 60 mL). Pain management will be the same as in the control group, except for QLBi. In the control group, QLBi is not performed.

Outcome(s)

Primary OutcomeMorphine usage within 24 hours after returning to the ward
Secondary Outcome1) Time from returning to the room to first administration of acetaminophen 2) NRS at rest (immediately after returning to the room, 1, 3, 6, and 24 hours after returning to the room) 3) PONV incidence within 24 hours after returning to the room 4) Patient satisfaction 5) Presence or absence of delirium within 24 hours after returning to the room

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteriaPatients who meet all of the following criteria will be included. 1. Patients scheduled to undergo spinal fusion surgery at Th12 to L5 2. ASA-PS (American Society of Anesthesiologists) classification 1 to 2 at the time of consent 3. Informed consent for this study was obtained during the preoperative outpatient visit 4. Age 18 or older at the time of consent
Exclude criteriaPatients who meet any of the following criteria will be excluded from the study. 1) Patients who are expected to be unable to answer the NRS after surgery due to severe dementia or aftereffects of cerebral infarction, or who are unable to understand how to use IV-PCA 2) Patients with a history of hypersensitivity to ropivacaine or amide-type local anesthetics 3) Patients who have been receiving opioids since before surgery 4) Patients with reduced renal function with an estimated glomerular filtration rate (eGFR) of less than 30 ml/min/1.73 m2 since before surgery 5) Patients who are otherwise deemed ineligible by the anesthesiologist in charge

Related Information

Contact

Public contact
Name Keisuke Yoshida
Address 1-Hikarigaoka, Fukushima, Fuksuhima, Japan Hukushima Japan 960-1295
Telephone +81-245471342
E-mail kei-y7of@fmu.ac.jp
Affiliation Fukushima Medical University Hospital
Scientific contact
Name Keisuke Yoshida
Address 1-Hikarigaoka, Fukushima, Fuksuhima, Japan Hukushima Japan 960-1295
Telephone +81-245471342
E-mail kei-y7of@fmu.ac.jp
Affiliation Fukushima Medical University Hospital